C8 MediSensors, Inc., a San Jose-based company developing noninvasive continuous glucose monitoring for people with diabetes, has raised an additional $19m in Series C-1 funding.
C8 MediSensors’ leading investors participated in this round.
The company intends to use the funding for its upcoming product launch in Europe.
Led by C8 CEO Paul Zygielbaum, himself a person with diabetes, C8 MediSensors has pioneered the use of light, specifically Raman spectroscopy, to measure glucose non-invasively with a continuous glucose monitor that is worn around the abdomen and sends readings to the user’s smartphone.
The company has filed for CE Mark approval and plans to introduce their optical continuous glucose monitor in Europe in the second half of 2012, pending regulatory approval.